One important metric to look for in a stock is an 80 or higher Relative Strength Rating. ACADIA Pharmaceuticals cleared that benchmark Tuesday, with a jump from 79 to 82 Tuesday.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating north of 80 as they launch their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
ACADIA Pharmaceuticals has climbed more than 5% past an 18.71 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
ACADIA Pharmaceuticals showed 0% EPS growth in its most recent report, while sales growth came in at 18%.
The company holds the No. 15 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, Catalyst Pharmaceuticals and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
